Lyra therapeutics fully enrolls pivotal phase 3 enlighten 2 trial of lyr-210 for the treatment of chronic rhinosinusitis

-- topline results expected q2 2025 -- watertown, mass., oct. 15, 2024 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra) (“lyra” or the “company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (crs), today announced that the pivotal phase 3 enlighten 2 clinical trial of lyr-210 in adult patients with crs who have not had prior ethmoid sinus surgery, is fully enrolled. lyr-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate) to the sinonasal passages for the treatment of crs. topline results from enlighten 2 are expected in q2 2025.
LYRA Ratings Summary
LYRA Quant Ranking